Javier Cortés, MD

home / authors / javier-cortés-md

Articles

27 Elacestrant vs Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer With ESR1-Mutated Tumors: ESR1 Allelic Frequencies and Clinical Activity From the Phase 3 EMERALD Trial

27 Elacestrant vs Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer With ESR1-Mutated Tumors: ESR1 Allelic Frequencies and Clinical Activity From the Phase 3 EMERALD Trial

Aditya Bardia, MD, MPH;Javier Cortés, MD;Francois Clement Bidard;Guillermo Streich;José García-Sáenz;Janice Lu, MD, PhD ;Giulia Tonini;Simona Scartoni;Alessandro Paoli;Alessio Fiascarelli;Alessandro Bressan;Monica Binaschi;Tomer Wasserman;Virginia Kaklamani, MD, DSc
June 19th 2025
36 Expert Perspectives in the Management of Breast Cancer Brain Metastases: A Survey of 32 International Specialists

36 Expert Perspectives in the Management of Breast Cancer Brain Metastases: A Survey of 32 International Specialists

Sarah Hertrich;Komal Jhaveri;Javier Cortés, MD;Sara Hurvitz, MD;Brian Moss;Chloe Gianatasio
June 14th 2025
TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy

TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy

Antonio Llombart-Cussac;José Manuel Pérez-García;Elena Lopez-Miranda;Rui Rui Zhang;Miguel Sampayo-Cordero;Juliana Carvalho-Santos;Olga Boix;Marta Beltran;Carlos Barrios;Guiseppe Curigliano;Rupert Bartsch;Anne Clair Hardy Bessard;Anna Compagnoni;Kathy Puyana Theall;Thomas Buechele;Tomer Wasserman;Javier Cortés, MD
May 28th 2025
45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

Heather McArthur, MD, MPH;Rebecca Dent, MD;Rina Hui;Yeon Hee Park;Peter Schmid, MD;Jing Wei;Jaime Mejia;Wilbur Pan;Javier Cortés, MD
May 27th 2025
46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study

46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study

Heather McArthur, MD, MPH;Peter A. Fasching;Rebecca Dent, MD;Javier Cortés, MD;Lajos Pusztai, MD, DPhil;Sherko Kuemmel;Carsten Denkert;Yeon Hee Park;Rina Hui;Nadia Harbeck, MD, PhD;Masato Takahashi;Seock-Ah Im;Michael Untch, MD, PhD;Marie-Ange Mouret-Reynier;Theodoros Foukakis;Marta Ferreira;Fatima Cardoso;Yu Ding;Cecilia Pinheiro;Jaime Mejia;Joyce A. O’Shaughnessy;Peter Schmid, MD
May 26th 2025
86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study

86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study

Hope S. Rugo, MD;Sara M. Tolaney, MD, MPH;Nancy Chan;Erika P. Hamilton, MD;Marina Sharifi;Kristine Rinn;Wassim McHayleh;Rinat Yerushalmi;Neelima Vidula, MD;Joyce O’Shaughnessy, MD;Guiseppe Curigliano;Javier Cortés, MD;Paula Muñoz Romero;Bartomeu Piza Vallespir;Kathy Puyana Theall;Alessandro Paoli;Monica Binaschi;Tomer Wasserman;Virginia Kaklamani, MD, DSc
April 25th 2025
87 Elacestrant Plus Abemaciclib Combination in Patients With Estrogen Receptor-positive, HER2-Negative Advanced or Metastatic Breast Cancer

87 Elacestrant Plus Abemaciclib Combination in Patients With Estrogen Receptor-positive, HER2-Negative Advanced or Metastatic Breast Cancer

Hope S. Rugo, MD;Sara M. Tolaney, MD, MPH;Nancy Chan;Erika P. Hamilton, MD;Eva Ciruelos;Ji-Yeon Kim;Elena López-Miranda;Elia Seguí;Neelima Vidula, MD;Joyce O’Shaughnessy, MD;Guiseppe Curigliano;Javier Cortés, MD;Alessandro Di Sanzo;Paula Muñoz Romero;Bartomeu Piza Vallespir;Manuel Dominguez;Kathy Puyana Theall;Alessandro Paoli;Monica Binaschi;Tomer Wasserman;Virginia Kaklamani, MD, DSc
April 24th 2025
11 Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER+/HER2– Breast Cancer: KEYNOTE-756

11 Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER+/HER2– Breast Cancer: KEYNOTE-756

Fatima Cardoso;Joyce O’Shaughnessy, MD;Heather McArthur, MD, MPH;Peter Schmid, MD;Javier Cortés, MD;Nadia Harbeck, MD, PhD;Melinda L. Telli, MD;David W. Cescon;Peter A. Fasching;Zhimin Shao;Delphine Loirat;Yeon Hee Park;Manuel Gonzalez Fernandez;Gábor Rubovszky;Seock-Ah Im;Rina Hui;Toshimi Takano;Fabrice André;Hiroyuki Yasojima;Zhenzhen Liu;Yu Ding;Liyi Jia;Vassiliki Karantza;Konstantinos Tryfonidis;Aditya Bardia, MD, MPH
August 18th 2024
12 EMERALD Trial Analysis of Patient-Reported Outcomes (PROs) in Patients (pts) With ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) Comparing Oral Elacestrant vs Standard-of-Care (SoC) Endocrine Therapy

12 EMERALD Trial Analysis of Patient-Reported Outcomes (PROs) in Patients (pts) With ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) Comparing Oral Elacestrant vs Standard-of-Care (SoC) Endocrine Therapy

Javier Cortés, MD;François-Clément Bidard;Aditya Bardia, MD, MPH;Virginia G. Kaklamani, MD, DSc;Ioanna Vlachaki;Giulia Tonini;Nassir Habboubi;Philippe Aftimos
August 17th 2024
16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation

16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation

Matthew P. Goetz, MD;Seth A. Wander;Thomas Bachelot;Gerald Batist;Javier Cortés, MD;Massimo Cristofanilli, MD;Giuseppe Curigliano;Alexandre de Nonneville;Einav Nili Gal-Yam;Komal Jhaveri;Cynthia X. Ma, MD, PhD;Heather A. Parsons, MD, MPH;Hope S. Rugo, MD;Sarah L. Sammons;Daniel G. Stover;Chris Twelves, MD, FRCP;Aditya Bardia, MD, MPH;Paul V. Plourde;David J. Portman;Senthil Damodaran
August 12th 2024
20 Final Overall Survival (OS) Analysis From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) in Patients (pts) With Hormone Receptor–Positive/HER2-Negative (HR+/HER2–) Metastatic Breast Cancer (mBC)

20 Final Overall Survival (OS) Analysis From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) in Patients (pts) With Hormone Receptor–Positive/HER2-Negative (HR+/HER2–) Metastatic Breast Cancer (mBC)

Sara M. Tolaney, MD, MPH;Aditya Bardia, MD, MPH;Frederik Marmé;Javier Cortés, MD;Peter Schmid, MD;Delphine Loirat;Olivier Trédan;Eva Ciruelos;Florence Dalenc;Patricia Gómez Pardo;Komal L. Jhaveri;Rosemary Delaney;Theresa Valdez;Oh Kyu Yoon;Hao Wang;Wendy Verret;Hope S. Rugo, MD
August 8th 2024
31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

Hope S. Rugo, MD;Nadia Harbeck, MD, PhD;Priya Rastogi, MD;Joyce O’Shaughnessy, MD;Frances Boyle;Javier Cortés, MD;Matthew P. Goetz, MD;Erika P. Hamilton, MD;Chiun-Sheng Huang;Elżbieta Senkus;Alexey Tryakin;Patrick Neven, MD, PhD;Jens Huober, MD;Ran Wei;Valérie André;Maria Munoz;Belen San Antonio;Ashwin Shahir;Miguel Martin, MD, PhD;Stephen Johnston
July 9th 2024
Javier Cortés, MD, on the CLEOPATRA Trial

Javier Cortés, MD, on the CLEOPATRA Trial

Javier Cortés, MD
October 15th 2015

In this interview we discuss the results of the CLEOPATRA trial, which studied the effect of adding pertuzumab to docetaxel and trastuzumab on HER2-positive metastatic breast cancer.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Expanding Immunotherapy Use in Early-Stage Breast Cancer
Published: July 14th 2025 | Updated: July 25th 2025
Expanding Immunotherapy Use in Early-Stage Breast Cancer